Please login to the form below
gemcitabine
This page shows the latest gemcitabine news and features for those working in and with pharma, biotech and healthcare.
Merck chases Roche with triple-negative breast cancer data for Keytruda
The actual progression-free survival (PFS) numbers for KEYNOTE-355 – which compared Keytruda plus Bristol-Myers Squibb/Celgene’s Abraxane (nab-paclitaxel), paclitaxel or gemcitabine/carboplatin to the chemo drugs given
Latest news
-
Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial
after first-line gemcitabine-based treatment.
-
Keytruda monotherapy fails in triple negative breast cancer
By contrast, Merck &Co’s phase 3 Keynote-119 trial evaluated Keytruda as a monotherapy for the second or third-line treatment compared to chemotherapy (capecitabine, eribulin, gemcitabine or vinorelbine). ... One such study is Keynote-355, which looks
-
Celgene’s Abraxane fails pancreatic cancer trial
Expectations for a positive outcome for the trial weren’t high, particularly as it used gemcitabine as a control. ... Since APACT was started, a new regimen called mFOLFIRINOX – based on oxaliplatin, leucovorin, irinotecan, and fluorouracil – has
-
CTI slumps as Servier-partnered lymphoma drug fails
gemcitabine in aggressive B-cell NHL, but found that CTI’s drug was unable to improve progression-free survival (PFS), its primary endpoint.
-
NICE knocks-back Shire's pancreatic cancer drug Onivyde
The watchdog was reviewing the treatment’s use in England and Wales for metastatic pancreatic cancer that has progressed after gemcitabine-based therapy.
Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial
Keytruda monotherapy fails in triple negative breast cancer
Celgene’s Abraxane fails pancreatic cancer trial
CTI slumps as Servier-partnered lymphoma drug fails
NICE knocks-back Shire's pancreatic cancer drug Onivyde
More from news
Approximately 1 fully matching, plus 50 partially matching documents found.
Latest Intelligence
-
The rise of chronic disease in BRIC markets
For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the
The rise of chronic disease in BRIC markets
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Battling breast cancer with precision medicine (Part 2)
I wanted her to access the best treatment possible. I also knew that carboplatin was especially effective when used with another chemotherapy called gemcitabine, as the two drugs are known to ... tested the PARP inhibitor with the gemcitabine-carboplatin
-
World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer
Unfortunately, recurrence rates in high-grade ovarian cancer mean that platinum resistance is a very real possibility, leaving second-line treatment such as gemcitabine, topotecan or liposomal doxorubicin less effective over
-
Marketing strategy in complex environments
cells. A good example of this is the combined use of Abraxane and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas – Abraxane helps to inhibit cancer cell growth, and ... gemcitabine encourages apoptosis of cell
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- WHO to test three more potential COVID-19 treatments
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA green lights study of phage-based drug for resistant infections
- First oral antiviral drug for COVID-19 reviewed by Health Canada
PMHub
Graphite
Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
